

## Recombinant Human IMP1/IMP A1 Protein (His Tag)

Catalog No. PKSH030519

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

|                                    |   |
|------------------------------------|---|
| <b>Synonyms</b>                    | Inositol Monophosphatase 1;IMP 1;IMPase 1;Inositol-1(or 4)-Monophosphatase 1;Lithium-Sensitive Myo-Inositol Monophosphatase A1;IMP A1;IMP A |
| <b>Species</b>                     | Human   |
| <b>Expression Host</b>             | E.coli  |
| <b>Sequence</b>                    | Met 1-Asp277  |
| <b>Accession</b>                   | P29218-1  |
| <b>Calculated Molecular Weight</b> | 32.4 kDa  |
| <b>Observed molecular weight</b>   | 32 kDa  |
| <b>Tag</b>                         | N-His   |
| <b>Bioactivity</b>                 | Not validated for activity  |

### Properties

|                       |   |
|-----------------------|---|
| <b>Purity</b>         | > 85 % as determined by reducing SDS-PAGE.  |
| <b>Endotoxin</b>      | Please contact us for more information.   |
| <b>Storage</b>        | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.     |
| <b>Shipping</b>       | This product is provided as lyophilized powder which is shipped with ice packs.   |
| <b>Formulation</b>    | Lyophilized from sterile PBS, 10 % glycerol, pH 7.4<br>Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.<br>Please refer to the specific buffer information in the printed manual. |
| <b>Reconstitution</b> | Please refer to the printed manual for detailed information.  |

### Data



> 85 % as determined by reducing SDS-PAGE.

### Background

The IMPA1 gene product is responsible for the final step of biotransformation of inositol triphosphate and diacylglycerol,

### For Research Use Only

two second messengers. Despite its many physiological functions, no clinical phenotype has been assigned to this gene dysfunction to date. Additionally, IMPA1 is the main target of lithium, a drug that is at the forefront of treatment for bipolar disorder.